JAGX - Why Jaguar Health Stock Is Up Today | Benzinga
Jaguar Health, Inc. (NASDAQ:JAGX) shares are trading higher Tuesday after the company announced it has signed an exclusive 5-year in-license agreement with Venture Life Group PLC.
The Details:
The license agreement is for the U.S. market for Venture Life's FDA-approved prescription product, Gelclair. Gelclair is used for the treatment of oral mucositis, also called “chemo mouth.”
“We are very happy to have executed the in-license agreement for Gelclair – and thus to have initiated Jaguar’s commercial footprint in our core focus area of cancer supportive care,” said Lisa Conte, Jaguar’s president and CEO.
Jaguar Health shares ...